Lonhala Magnair Kit is owned by Sunovion Resp.
Lonhala Magnair Kit contains Glycopyrrolate.
Lonhala Magnair Kit has a total of 13 drug patents out of which 1 drug patent has expired.
Expired drug patents of Lonhala Magnair Kit are:
Lonhala Magnair Kit was authorised for market use on 05 December, 2017.
Lonhala Magnair Kit is available in solution;inhalation dosage forms.
Lonhala Magnair Kit can be used as a method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd), long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
The generics of Lonhala Magnair Kit are possible to be released after 07 December, 2036.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7316067||SUNOVION RESP||Forming a perforate membrane by laser drilling and a subsequent electro-polishing step|| |
(4 months ago)
|US8511581||SUNOVION RESP||Fluid droplet production apparatus and method|| |
(9 months from now)
|US7458372||SUNOVION RESP||Inhalation therapy device|| |
(1 year, 9 months from now)
|US7931212||SUNOVION RESP||Fluid droplet production apparatus and method|| |
(2 years from now)
|US11278683||SUNOVION RESP||Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized|| |
(3 years from now)
|US9265900||SUNOVION RESP||Disposable ampoule for an aerosol generating device|| |
(5 years from now)
|US10940110||SUNOVION RESP||Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations|| |
(6 years from now)
|US9789270||SUNOVION RESP||Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized|| |
(7 years from now)
|US9168556||SUNOVION RESP||Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer|| |
(9 years from now)
|US9604018||SUNOVION RESP||Aerosol therapy device|| |
(10 years from now)
|US10376661||SUNOVION RESP||Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element|| |
(12 years from now)
|US10688518||SUNOVION RESP||Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator|| |
(13 years from now)
|US10744277||SUNOVION RESP||Aerosol delivery device and method of operating the aerosol delivery device|| |
(13 years from now)
Market Authorisation Date: 05 December, 2017
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd); A method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd)
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic